Heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir in patients with Middle East respiratory syndrome by cytokine levels
© 2022. The Author(s)..
Animal and human data indicate variable effects of interferons in treating coronavirus infections according to inflammatory status and timing of therapy. In this sub-study of the MIRACLE trial (MERS-CoV Infection Treated with a Combination of Lopinavir-Ritonavir and Interferon β-1b), we evaluated the heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir versus placebo among hospitalized patients with MERS on 90-day mortality, according to cytokine levels and timing of therapy. We measured plasma levels of 17 cytokines at enrollment and tested the treatment effect on 90-day mortality according to cytokine levels (higher versus lower levels using the upper tertile (67%) as a cutoff point) and time to treatment (≤ 7 days versus > 7 days of symptom onset) using interaction tests. Among 70 included patients, 32 received interferon-β1b and lopinavir-ritonavir and 38 received placebo. Interferon-β1b and lopinavir-ritonavir reduced mortality in patients with lower IL-2, IL-8 and IL-13 plasma concentrations but not in patients with higher levels (p-value for interaction = 0.09, 0.07, and 0.05, respectively) and with early but not late therapy (p = 0.002). There was no statistically significant heterogeneity of treatment effect according to other cytokine levels. Further work is needed to evaluate whether the assessment of inflammatory status can help in identifying patients with MERS who may benefit from interferon-β1b and lopinavir-ritonavir. Trial registration: This is a sub-study of the MIRACLE trial (ClinicalTrials.gov number, NCT02845843).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Scientific reports - 12(2022), 1 vom: 28. Okt., Seite 18186 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arabi, Yaseen M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2494G1JF75 |
|---|
| Anmerkungen: |
Date Completed 02.11.2022 Date Revised 29.12.2022 published: Electronic ClinicalTrials.gov: NCT02845843 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-022-22742-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348217838 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348217838 | ||
| 003 | DE-627 | ||
| 005 | 20231226205456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-022-22742-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM348217838 | ||
| 035 | |a (NLM)36307462 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arabi, Yaseen M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir in patients with Middle East respiratory syndrome by cytokine levels |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2022 | ||
| 500 | |a Date Revised 29.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02845843 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Animal and human data indicate variable effects of interferons in treating coronavirus infections according to inflammatory status and timing of therapy. In this sub-study of the MIRACLE trial (MERS-CoV Infection Treated with a Combination of Lopinavir-Ritonavir and Interferon β-1b), we evaluated the heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir versus placebo among hospitalized patients with MERS on 90-day mortality, according to cytokine levels and timing of therapy. We measured plasma levels of 17 cytokines at enrollment and tested the treatment effect on 90-day mortality according to cytokine levels (higher versus lower levels using the upper tertile (67%) as a cutoff point) and time to treatment (≤ 7 days versus > 7 days of symptom onset) using interaction tests. Among 70 included patients, 32 received interferon-β1b and lopinavir-ritonavir and 38 received placebo. Interferon-β1b and lopinavir-ritonavir reduced mortality in patients with lower IL-2, IL-8 and IL-13 plasma concentrations but not in patients with higher levels (p-value for interaction = 0.09, 0.07, and 0.05, respectively) and with early but not late therapy (p = 0.002). There was no statistically significant heterogeneity of treatment effect according to other cytokine levels. Further work is needed to evaluate whether the assessment of inflammatory status can help in identifying patients with MERS who may benefit from interferon-β1b and lopinavir-ritonavir. Trial registration: This is a sub-study of the MIRACLE trial (ClinicalTrials.gov number, NCT02845843) | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Asiri, Ayed Y |e verfasserin |4 aut | |
| 700 | 1 | |a Assiri, Abdullah M |e verfasserin |4 aut | |
| 700 | 1 | |a Abdullah, Mashan L |e verfasserin |4 aut | |
| 700 | 1 | |a Aljami, Haya A |e verfasserin |4 aut | |
| 700 | 1 | |a Balkhy, Hanan H |e verfasserin |4 aut | |
| 700 | 1 | |a Al Jeraisy, Majed |e verfasserin |4 aut | |
| 700 | 1 | |a Mandourah, Yasser |e verfasserin |4 aut | |
| 700 | 1 | |a AlJohani, Sameera |e verfasserin |4 aut | |
| 700 | 1 | |a Al Harbi, Shmeylan |e verfasserin |4 aut | |
| 700 | 1 | |a Jokhdar, Hani A Aziz |e verfasserin |4 aut | |
| 700 | 1 | |a Deeb, Ahmad M |e verfasserin |4 aut | |
| 700 | 1 | |a Memish, Ziad A |e verfasserin |4 aut | |
| 700 | 1 | |a Jose, Jesna |e verfasserin |4 aut | |
| 700 | 1 | |a Ghazal, Sameeh |e verfasserin |4 aut | |
| 700 | 1 | |a Al Faraj, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Al Mekhlafi, Ghaleb A |e verfasserin |4 aut | |
| 700 | 1 | |a Sherbeeni, Nisreen Murad |e verfasserin |4 aut | |
| 700 | 1 | |a Elzein, Fatehi Elnour |e verfasserin |4 aut | |
| 700 | 1 | |a Hayden, Frederick G |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a AlMutairi, Badriah M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Dawood, Abdulaziz |e verfasserin |4 aut | |
| 700 | 1 | |a Alharbi, Naif Khalaf |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 28. Okt., Seite 18186 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:28 |g month:10 |g pages:18186 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-022-22742-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 28 |c 10 |h 18186 | ||